EE+ POEM Archive
SGLT2 inhibitors reduce cardiovascular mortality but benefit is modest, even in patients with established heart disease (NNT = 200 for 3 years)
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Barry, Henry, et al., editors. "SGLT2 Inhibitors Reduce Cardiovascular Mortality but Benefit Is Modest, Even in Patients With Established Heart Disease (NNT = 200 for 3 Years)." EE+ POEM Archive, John Wiley & Sons, 2024. Evidence Central, evidence.unboundmedicine.com/evidence/view/infoPOEMs/3377224/all/SGLT2_inhibitors_reduce_cardiovascular_mortality_but_benefit_is_modest__even_in_patients_with_established_heart_disease__NNT_=_200_for_3_years_.
SGLT2 inhibitors reduce cardiovascular mortality but benefit is modest, even in patients with established heart disease (NNT = 200 for 3 years). In: Barry HH, Ebell MHM, Shaughnessy AFA, et al, eds. EE+ POEM Archive. John Wiley & Sons; 2024. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/3377224/all/SGLT2_inhibitors_reduce_cardiovascular_mortality_but_benefit_is_modest__even_in_patients_with_established_heart_disease__NNT_=_200_for_3_years_. Accessed December 3, 2024.
SGLT2 inhibitors reduce cardiovascular mortality but benefit is modest, even in patients with established heart disease (NNT = 200 for 3 years). (2024). In Barry, H., Ebell, M. H., Shaughnessy, A. F., & Slawson, D. C. (Eds.), EE+ POEM Archive. John Wiley & Sons. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/3377224/all/SGLT2_inhibitors_reduce_cardiovascular_mortality_but_benefit_is_modest__even_in_patients_with_established_heart_disease__NNT_=_200_for_3_years_
SGLT2 Inhibitors Reduce Cardiovascular Mortality but Benefit Is Modest, Even in Patients With Established Heart Disease (NNT = 200 for 3 Years) [Internet]. In: Barry HH, Ebell MHM, Shaughnessy AFA, Slawson DCD, editors. EE+ POEM Archive. John Wiley & Sons; 2024. [cited 2024 December 03]. Available from: https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/3377224/all/SGLT2_inhibitors_reduce_cardiovascular_mortality_but_benefit_is_modest__even_in_patients_with_established_heart_disease__NNT_=_200_for_3_years_.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - SGLT2 inhibitors reduce cardiovascular mortality but benefit is modest, even in patients with established heart disease (NNT = 200 for 3 years)
ID - 3377224
ED - Barry,Henry,
ED - Ebell,Mark H,
ED - Shaughnessy,Allen F,
ED - Slawson,David C,
BT - EE+ POEM Archive
UR - https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/3377224/all/SGLT2_inhibitors_reduce_cardiovascular_mortality_but_benefit_is_modest__even_in_patients_with_established_heart_disease__NNT_=_200_for_3_years_
PB - John Wiley & Sons
DB - Evidence Central
DP - Unbound Medicine
ER -
